Kornimate/medical-research-clean huggingface dataset:
sun yat-sen cohort of cns idiopathic inflammatory demyelinating diseases

Conditions: Multiple Sclerosis, MS; Neuromyelitis Optica Spectrum Disorders; Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease; Acute Disseminated Encephalomyelitis; Clinically Isolated Syndrome; Demyelinating Disorder

Summary: the goal of this observational study is to learn about pathogenesis and clinical prognosis of cns iidd in the chinese population and to provide evidence-based clues for clinical treatment decisions. the main questions it aims to answer are: question 1: clarify the clinical characteristics and prognostic factors of various diseases (ms, nmosd, mogad, etc.) within iidd in the chinese population. question 2: analyze the relationship between biomarkers and the occurrence, progression, and prognosis of cns iidd cases in our hospital. participants will 1. receive the recommended diagnosis and treatment plans from current international and national guidelines or expert consensus, without additional special interventions. 2. receive clinical evaluation, follow-up, and management from dedicated neuroimmunology specialists.


Eligibility criteria:
inclusion criteria: 1. patients aged 18-65 years with central nervous system idiopathic inflammatory demyelinating diseases (cns iidd); 2. the clinical syndrome of the attack meets one of the following: ms, nmosd, mogad, adem, clinically isolated syndrome, demyelinating encephalopathy, demyelinating myelitis, or brainstem encephalitis (see below a-e); 3. agree to participate in this study and sign the informed consent form. exclusion criteria: 1. history of tumors or diagnosis of central nervous system tumors; 2. infectious lesions of the central nervous system; 3. hereditary, metabolic, toxic, vascular, or traumatic demyelinating diseases of the brain/spinal cord; 4. non-compliance with treatment and follow-up.

Keywords: cns iidd follow-up
heartphone cancer survivors trial 2019

Conditions: Breast Cancer; Leukemia; Lymphoma

Summary: this is a behavioral study that will examine changes in physical activity and vascular health in response to a digital tool (app) that will appear on participant's lock screen of their android phone. participants will be asked to use this app for 3 months and to wear a fitbit device continuously throughout the study. participants will be asked to complete questionnaires, participate in fitness testing and measures of cardiovascular health at 3 months and 6 months after baseline assessments. the hypothesis is that exposure to the app will lead to increased physical activity volume and improved microvessel function.


Eligibility criteria:
inclusion criteria: * age 18-65 years * diagnosis of breast cancer, leukemia, or lymphoma \<15 yrs * completed chemotherapy with cardiotoxic anthracycline-based agents 1+ year ago * english-proficiency * own \& use smartphone with android operating system main study and ancillary study exclusion criteria: * currently receiving curative treatment for cancer * 90+ min/week moderate (or greater) intensity pa * any medical contraindications on the physical activity readiness questionnaire * require an assistive device for mobility or has any other condition that may limit or prevent participation in moderate-intensity physical activity * current smoker * pregnant or planning to become pregnant in the next 6 mos/breastfeeding * allergy to test substances * allergy to latex ancillary study: * taking metformin * current medications that could conceivably alter the cardiovascular or thermoregulatory control or responses (e.g. beta blockers, calcium channel blockers, angiotensin receptor blockers)
temperature evaluation by mri thermometry during cervical cooling

Conditions: Healthy

Summary: the american heart association (aha) recommends cooling (inducing mild hypothermia) patients who were resuscitated following cardiac arrest but who remained comatose. induced mild hypothermia is now the standard of care for post-resuscitation patients in the intensive care unit (icu) setting. the use of cooling has recently moved to pre-hospital and emergency department (ed) application as more current studies show that early initiation of cooling significantly improves neurologic outcomes and survival rates instead of waiting until the patient arrives in the icu to initiate cooling. in the pre-hospital setting chilled saline (4°c) and packing the body in ice have been the primary methods to initiate induced mild hypothermia the excel cryo cooling system is a non-invasive cervical collar (c-collar) that provides cooling to the carotid arteries, the main blood supply to the brain, and allows for the rapid initiation of selective cerebral cooling. the investigators are planning to use mri-thermometry to see how quickly the excel cryo cooling collar can drop brain temperature when applied by itself. healthy volunteers will be used for this study to provide important temperature data on the effectiveness of the excel cryo cooling system. the investigators will be able to use the data from this project to further the current clinical research in induced mild hypothermia after cardiac arrest.


Eligibility criteria:
inclusion criteria: * \> 18 years of age * understands the risks involved, as detailed in the informed consent * no mri risk factors exclusion criteria: * \ 60 years of age * pregnant * any known medical problems that limit activity or decrease blood flow: underactive thyroid (hypothyroidism),poor nutrition, stroke, severe arthritis, parkinson's disease, dementia, significant mental illness besides clinical depression, spinal cord injuries, recent serious burn, disorders that affect sensation in the extremities (e.g., diabetic neuropathy)dehydration, and any condition that limits activity or restrains the normal flow of blood. * taking any medications (except seasonal allergy medication, over-the-counter nsaids, acetaminophen, or contraceptives) * oral medications that inhibit the body's ability to respond to cold: antidepressants, antipsychotics/neuroleptics, including phenothiazines, beta blockers, clonidine, meperidine, sedative-hypnotics. * history of cardiac condition in a family member younger than 40 years * inability to fit in the mri scanner (bmi \> 30 kg/m2) * mri risk factors (e.g., claustrophobia, heart condition, metal implants, etc), as detailed in the mri safety questionnaire heart rate, blood pressure, respiratory rate, or temperature outside of acceptable ranges.

Keywords: induced mild hypothermia cervical cooling collar mri brain thermometry mri thermometry rate-of-cooling excel cryo cooling collar
use of point-of-care lung ultrasound before and after surgery trying to predict post-operative pulmonary complications

Conditions: Ultrasonography; Postoperative Complications; Anesthesia; Surgery-Complications; Pulmonary Complication

Summary: patients undergoing surgery inside their abdomen, with no serious heart or lung diseases, will have a lung ultrasound exam before and after surgery. the patient respiratory status in the post-operative unit and the surgical ward will be monitored for complications after surgery

the study will be performed in the soroka hospital operating room and recovery unit. on admission to pre-surgery, patients will be investigates for inclusion and exclusion criteria. those that are eligible for the study will be asked to give formal consent to participate in the study. after consent the examiner will review the patient's past medical history and surgery plan, and will preform the pre-operative lus exam. after surgery, the examiner will review the electronic anesthesia record and will preform the post-operative lus exam within 30 minutes of arrival to the recovery unit or 30 minutes from extubation (in patients that were admitted to the recovery unit still under mechanical ventilation). upon discharge from the recovery unit the examiner will review the recovery unit electronic record. after discharge, the examiner will review the patient post-operative surgical ward electronic record.

Eligibility criteria:
inclusion criteria: the population study will include patients 18 years and older, with asa class i, ii or iii, presenting for elective intra-abdominal surgery under general anesthesia and are not planned for long-term post-surgical mechanical ventilation. exclusion criteria: patient will be excluded from the study if they have pre-existing moderate or severe heart or lung disease: a history of ischemic heart disease, moderate or severe systolic or diastolic heart failure, moderate or severe pulmonary hypertension, moderate or severe obstructive or interstitial lung disease. patients will also be excluded if they had a severe intra-operative pulmonary complication (laryngospasm, bronchospasm, anaphylaxis, emergency surgical airway). patients who require un-planned long term mechanical ventilation or those who died during surgery will also be excluded.
surveillance of rotavirus gastroenteritis in children <5 years

Conditions: Gastroenteritis; Rotavirus Infections

Summary: the purpose of this study is to monitor diarrheal disease and observe changes after the introduction of the rota vaccine.

monitoring of diarrheal disease and observe changes after the introduction of the rota vaccine comparing the epidemiology in jewish and bedouin population before and after the introduction of the rota vaccine into the national immunization program

Eligibility criteria:
inclusion criteria: 1. children \< 5 years with 2. gastro enteritis 3. visiting the er 4. residents of southern israel 5. signed informed concent - exclusion criteria: not all of the above

Keywords: surveillance rotavirus gastroenteritis children < 5 years of age southern israel signed informed concent
interest of ttc for the early diagnosis of acute myocardial infarction at autopsy

Conditions: Myocardial Infarction

Summary: ischemic heart disease is the leading cause of death worldwide and the leading cause of sudden cardiac death. however, its post-mortem diagnosis is particularly difficult because the gross examination of the heart is usually normal at the autopsy . the diagnosis is therefore often based on a set of indirect arguments, such as the patient's medical and clinical history and the degree of occlusion of the coronary arteries. the formal diagnosis of acute myocardial infarction (ami) currently relies on standard histological examination. however, histological findings often require a prolonged survival time of several hours to be highlighted. triphenyltetrazolium chloride (ttc) is a salt that reacts with lactate dehydrogenases contained in still viable myocardial cells, forming a red pigment visible to the naked eye, (1,3,5 triphenylformazan). ischemia-induced cell death, which occurs within minutes of the causative event, is responsible for the leakage of lactate deshydrogenase into the extracellular medium and thus results in the absence of formazan formation in the infarcted area, which displays an easily identifiable pale unstained color. it has been suggested that the use of ttc would allow the identification of mi as early as one hour of survival in animal models, before the usual macroscopic and microscopic signs are visible. it could therefore represent an attractive forensic tool for the early diagnosis of ami at the autopsy.


Eligibility criteria:
inclusion criteria: * adult patients autopsied at the forensic institute of the chu of montpellier whose ante-mortem (medical history, cardiovascular risk factors, clinical history) and autopsy data (significant coronary stenosis associated or not with an endoluminal thrombus, scars of old infarction, absence of other identified cause of death) suggest ami as the cause of death. * known survival time and postmortem interval. exclusion criteria: - putrefied bodies

Keywords: early acute myocardial infarction ttc sudden death early markers biochemicla markers
a mobile app-based study to evaluate disease burden and treatment patterns in immunoglobulin a nephropathy (igan) in the us

Conditions: Immunoglobulin A Nephropathy

Summary: the study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (hrqol) experienced by immunoglobulin a nephropathy (igan) patients and their caregivers.

this will be a prospective, observational study. data will be collected using the folia health platform. participation in the study will occur through use of the folia mobile platform, where study participants will be directed to a study-specific platform environment to review and sign the consent form and enroll. each participant will complete an initial 6-month study data collection period which includes home reported outcomes (hro) tracking along with study specific components including a baseline survey, monthly check-in prompts, and endline study evaluation survey. after the 6-month period, participants can continue to use folia to track their hros for their own personal use. with their consent, the data they enter after the initial 6-month period may be reviewed for ongoing data integrations with novartis apprise data platform for up to 2 years.

Eligibility criteria:
inclusion criteria: * diagnosis of igan, regardless of symptom or treatment history * adult aged 18 or older; adult caregiver to an adult patient aged 18 or older; or adult caregiver to a pediatric patient under 18 years of age * us-based with a proficient understanding of and ability to read the english language exclusion criteria: none

Keywords: igan hrqol iptacopan atrasentan immunoglobulin a nephropathy
study of erbitux™ (cetuximab) in pediatric patients with refractory solid tumors

Conditions: Cancer; Refractory Solid Tumor

Summary: the purpose of this clinical research study is to establish the maximum tolerated dose and recommended phase ii dose of erbitux™ in combination with irinotecan in pediatric and adolescent patients with refractory solid tumors.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of a solid tumor which has progressed on, or following standard therapy, or for which no standard effective therapy is known. * children age 1-18 years. exclusion criteria: * presence of active infection. * requirement to receive concurrent chemotherapy immunotherapy, radiotherapy, or any other investigational drug while on study. * inadequate bone marrow, hepatic, or renal function.
severity indices of diquat poisoning for triage and prognosis in acute diquat poisoning

Conditions: Diquat Poisoning

Summary: to enable emergency physicians to make well-informed triage and treatment decisions, accurate tools to evaluate the severity of diquat poisoning are needed. this study establishes severity indices for diquat poisoning (sidps) in assessing the risk of death for patients with acute diquat poisoning for triage purposes and 28-day mortality.

self-poisoning with pesticides is a global public health concern, and its effective control is of importance in reducing both morbidity and mortality. in china, poisoning consistently ranked as the fifth leading cause of death from 2009 to 2013, and the overall incidence rate was 39.43/100,000 population in 2019, with intentional poisoning, mostly related to self-harm. paraquat (1,1'-dimethyl-4,4'-bipyridinium) and, after its ban in china, diquat (1,1'-ethylene-2, 2'-bipyridinium) are the agents with the highest rate of mortality due to their inherent toxicity affecting various organs paired with a lack of effective treatments. as reported from different hospitals, the inhospital case fatality rate of diquat poisoning was 18.6%, whereas the proportion of case fatalities increased to 60% after follow-up in china. although uncommon, diquat poisoning occurs in many countries, including the united states, where 2,128 cases were identified between 1998 and 2011, and 466 cases were documented in 2023, according to the annual report of the national poison data system. the lethality of diquat underscores the necessity for precise prognosis. estimating survival probability empowers physicians to tailor treatment decisions for patients and enhance communication, especially given the variability in capability of emergency departments (eds) around the world.

Eligibility criteria:
the following criteria were used for patient inclusion: 1. history of oral exposure to diquat solution reported by patient or proxy; 2. a specimen for the diquat plasma concentration collected immediately upon admission; 3. documentation that patients or, in case of unconsciousness of the patient, legal proxies were aware of and agreed to treatment plans. patients were excluded if: 1. they had ingested other toxicants in addition to diquat; 2. diquat was not detected in biological samples; 3. patients with over half of incomplete information; 4. patients with an exposure time (time from exposure to presentation at ed) longer than 48 hours.

Keywords: diquat poisoning triage prognosis survival analysis
additive effects of qvar to (seretide) on surrogate markers of airway inflammation in refractory asthma

Conditions: Asthma

Summary: the purpose of this study is to establish whether addition of extra-fine particle steroid inhalers achieve additional suppression of small airways inflammation when added to 'standard' fluticasone/salmeterol combination therapy in refractory asthma.


Eligibility criteria:
inclusion criteria: * refractory, non-smoking asthmatics with fev1 les than 80% predicted * rv greater than 100% predicted and cano greater than 3ppb when stepped up to 1000µg of fluticasone per day, with or without additional asthma medication. * informed consent and ability to perform exhaled nitric oxide assessment. * participants must be on greater than 500mcg of fluticasone per day to enter dose ramp run-in. exclusion criteria: * recent respiratory infection or oral steroid use. * pregnancy or lactation. * known or suspected contra-indication to any of the imp's. * cano less than 3ppb, fev1 greater than 80% or rv less than 100% at post-optimisation visit.
lidocaine spray plus oral celecoxib for pain control during hysterosalpingography

Conditions: IUCD Complication

Summary: our aims to investigate the effectiveness of10% lidocaine spray plus oral celecoxib for pain control during hysterosalpingography

hysterosalpingography can cause pain and discomfort in several ways: use of the tenaculum to grasp the cervix and straighten the uterus for proper insertion; trans-cervical actions including measuring uterine depth, inserting the cannula; and injection of the dye

Eligibility criteria:
inclusion criteria: * any patient came for hysterosalpingography exclusion criteria: * any patient has contraindication to hysterosalpingography
the effectiveness of sertraline in patients who have had inadequate response to escitalopram

Conditions: Major Depressive Disorder

Summary: the purpose of this is to determine the efficacy, safety, and tolerability of sertraline in patients with major depressive disorder (mdd) who have shown inadequate response ot escitalopram.

eight week open-label flexible dose trial in adult outpatients diagnosed with major depressive disorder (mdd) who have had a prior failure with escitalopram. failure is operationally defined as either premature discontinuation because of side effects or the report of an incomplete response to escitalopram, minimum dose 10mg/day, maintain for 3 weeks or more. 10mg/day was chosen because 1) it is the most commonly prescribed single dose of escitalopram in clinical practice, 2) it is equivalent to approx. 30mg/day of arcemic citalopram and 3) escitalopram has very high potency at the serotonin transporter (ki=1.1); this means that escitalopram would be expected to saturate the transporter at relatively low doses. a total of twenty patients will be treated.

Eligibility criteria:
inclusion criteria: * primary dsm-iv diagnosis of major depressive episode of mdd without psychotic symptoms. additional axis i diagnoses will be permitted only if they are identified as secondary diagnoses * ham-d 21 item score of greater than or equal to 18 * age 18 and above * ability and willingness to provide consent for participation * failure to respond to escitalopram exclusion criteria: * diagnosis of bipolar disorder or any psychotic disorder * alcohol or drug abuse or dependence currently or in the last 6 months * a history of non-response or intolerance to sertraline at least 50 mg. for at least 4 weeks or more * concomitant use of another antidepressant or use of an antidepressant within 2 weeks of baseline (4 weeks for fluoxetine) * use within 1 week of baseline, or concomitant use of any psychotropics with the exception of zolpidem for sleep * use within 4 weeks of baseline or concomitant use of benzodiazepines with the exception of prn use of diazepam 10 mg/day or its equivalent * presence of serious and/or unstable medical condition * score of 3 or 4 on the suicide item (item 3) of the ham-d scale * known sensitivity of sertraline

Keywords: failure to escitalopram
phase ii study of da-6034 eye drops in dry eye syndrome

Conditions: Dry Eye Syndrome

Summary: this study is to determine the efficacy and safety of 3% or 5% da-6034 eye drops compared with placebo in dry eye syndrome.

eligible subjects are randomly assigned to receive 3% da-6034, 5% da-6034 or placebo. this study is conducted for 6 weeks(run-in period 2 weeks + treatment period 4 weeks).

Eligibility criteria:
inclusion criteria: 1. age≥20 2. dry eye symptoms(irritation, foreign body sensation, burning, mucus discharge, blurring, itching, photophobia, tird or heavy feeling, pain) for more than 6 months 3. fluorescein corneal staining score ≥ 4 and schirmer test i ≤ 7mm in same eye 4. corrected vision ≥ 0.2 in both eye 5. have given a written, informed consent exclusion criteria: 1. ocular disorder that may confound interpretation of study results 2. current treatment for glaucoma or iop over 25mmhg 3. ocular surgery history within 1 year 4. other malignancy history or uncontrolled severe disease within 5 years 5. use of systemic immunosuppressive therapies within 3 months 6. use of opthalmic cyclosporin, opthalmic steroid within 4 weeks 7. received any other investigational drugs within 4 weeks 8. subjects who are willing to wear contact lenses during study participation 9. pregnant or lactating women

Keywords: dry eye syndrome
effect of an internet based compliance enhancement tool in subjects with hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: the purpose of the study is to determine whether an internet based compliance tool is superior to common diet counselling in patients with hypercholesterolemia.


Eligibility criteria:
inclusion criteria: * available personal mailbox and access to the internet * primary hypercholesterolemia with cv risk \> 20% over 10 years judged by the investigator or a history of ischemic heart disease or other established atherosclerotic disease (claudicatio intermittens, apoplexia cerebri (ischaemic stroke)) or stable diabetes mellitus * fasting ldl-c level \> 3.2 mmol/l exclusion criteria: * known heterozygous or homozygous familial hypercholesterolemia or known type iii hyperlipoproteinaemia (familial dysbetalipoproteinaemia) * documented secondary hypercholesterolemia of any cause except stable diabetes mellitus (type 1 or type 2) * history of serious adverse effect or hypersensitivity reactions to statins, in particular any history of myopathy